ALEC Stock Forecast 2025-2026
Distance to ALEC Price Targets
ALEC Price Momentum
10 Quality Stocks Worth Considering Now
Researching Alector (ALEC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ALEC and similar high-potential opportunities.
Latest ALEC Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, ALEC has a bullish consensus with a median price target of $4.00 (ranging from $1.00 to $8.56). The overall analyst rating is Buy (7.8/10). Currently trading at $1.45, the median forecast implies a 175.9% upside. This outlook is supported by 6 Buy, 1 Hold, and 2 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ALEC Analyst Ratings
ALEC Price Target Range
Latest ALEC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ALEC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 7, 2025 | Morgan Stanley | Sean Laaman | Underweight | Assumes | $1.50 |
| Feb 27, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $7.00 |
| Dec 16, 2024 | Stifel | Paul Matteis | Hold | Downgrade | $4.00 |
| Nov 26, 2024 | BTIG | Thomas Shrader | Buy | Maintains | $5.00 |
| Nov 26, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $0.00 |
| Nov 26, 2024 | Morgan Stanley | Matthew Harrison | Underweight | Downgrade | $3.00 |
| Nov 7, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Sep 17, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Sep 9, 2024 | Cantor Fitzgerald | Josh Schimmer | Overweight | Reiterates | $0.00 |
| Jul 29, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $0.00 |
| Jun 20, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $35.00 |
| Jun 20, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $0.00 |
| May 9, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $0.00 |
| May 9, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $35.00 |
| Feb 28, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $41.00 |
| Dec 14, 2023 | Stifel | Paul Matteis | Buy | Upgrade | $15.00 |
| Dec 12, 2023 | Deutsche Bank | Neena Bitritto-Garg | Buy | Initiates | $12.00 |
| Nov 17, 2023 | Mizuho | Graig Suvannavejh | Buy | Maintains | $9.00 |
| Sep 25, 2023 | Goldman Sachs | Madhu Kumar | Sell | Initiates | $4.00 |
| Sep 22, 2023 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Initiates | $13.00 |
Alector Inc. (ALEC) Competitors
The following stocks are similar to Alector based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alector Inc. (ALEC) Financial Data
Alector Inc. has a market capitalization of $143.67M with a P/E ratio of -1.2x. The company generates $100.56M in trailing twelve-month revenue with a -118.4% profit margin.
Revenue growth is +257.1% quarter-over-quarter, while maintaining an operating margin of -13.4% and return on equity of -91.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Alector Inc. (ALEC) Business Model
About Alector Inc.
Develops therapeutics for neurodegenerative diseases.
Alector Inc. generates revenue through the research and development of innovative therapies targeting neurodegenerative diseases by leveraging the immune system. The company collaborates with leading research institutions and industry partners to advance its clinical programs, which may lead to potential licensing agreements or partnerships that further monetize its discoveries.
Headquartered in South San Francisco, California, Alector is positioned at the intersection of immunology and neurology, addressing unmet medical needs in the treatment of diseases like Alzheimer's and frontotemporal dementia. Its pioneering approach could reshape treatment strategies within the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
238
CEO
Dr. Arnon Rosenthal Ph.D.
Country
United States
IPO Year
2019
Website
www.alector.comAlector Inc. (ALEC) Latest News & Analysis
Alector, Inc. (NASDAQ: ALEC) will hold its Q4 2024 Earnings Conference Call on February 26, 2025, at 4:30 PM ET. Key company executives will participate in the call.
Alector's Q4 2024 earnings call will provide insights into financial performance and strategic direction, influencing investor sentiment and potential stock valuation.
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
18 days agoAlector expects INFRONT-3 Phase 3 trial data for latozinemab by Q4 2025 and aims to complete PROGRESS-AD Phase 2 enrollment by mid-2025. The company has $413.4 million in cash, ensuring funding through 2026.
Upcoming clinical trial results and cash reserves indicate potential growth and stability for the company. Positive outcomes may attract interest and drive stock performance in the biotech sector.
Alector (ALEC) reported a quarterly loss of $0.02 per share, significantly better than the Zacks Consensus Estimate of $0.64 and an improvement from a loss of $0.49 per share a year earlier.
Alector's smaller-than-expected loss signals improved financial health, potentially boosting investor confidence and affecting stock performance positively.
Alector, Inc. (Nasdaq: ALEC) will participate in upcoming investor conferences, focusing on therapies for neurodegeneration.
Alector's participation in investor conferences signals potential updates on clinical developments, impacting investor sentiment and stock performance.
Alector, Inc. (Nasdaq: ALEC) will hold a conference call and webcast on February 26, 2025, at 4:30 p.m. to discuss its neurodegeneration therapies.
Alector's upcoming conference call may provide critical updates on its clinical progress and potential therapies, influencing investor sentiment and stock performance.
The company is advancing its preclinical and research pipeline, focusing on programs combined with Alector Brain Carrier to develop genetically-validated therapies for neurodegeneration.
Advancements in the preclinical pipeline and collaboration with Alector Brain Carrier signal potential breakthroughs in neurodegenerative therapies, which could drive future revenue and stock performance.
Frequently Asked Questions About ALEC Stock
What is Alector Inc.'s (ALEC) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Alector Inc. (ALEC) has a median price target of $4.00. The highest price target is $8.56 and the lowest is $1.00.
Is ALEC stock a good investment in 2025?
According to current analyst ratings, ALEC has 6 Buy ratings, 1 Hold ratings, and 2 Sell ratings. The stock is currently trading at $1.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ALEC stock?
Wall Street analysts predict ALEC stock could reach $4.00 in the next 12 months. This represents a 175.9% increase from the current price of $1.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alector Inc.'s business model?
Alector Inc. generates revenue through the research and development of innovative therapies targeting neurodegenerative diseases by leveraging the immune system. The company collaborates with leading research institutions and industry partners to advance its clinical programs, which may lead to potential licensing agreements or partnerships that further monetize its discoveries.
What is the highest forecasted price for ALEC Alector Inc.?
The highest price target for ALEC is $8.56 from at , which represents a 490.3% increase from the current price of $1.45.
What is the lowest forecasted price for ALEC Alector Inc.?
The lowest price target for ALEC is $1.00 from at , which represents a -31.0% decrease from the current price of $1.45.
What is the overall ALEC consensus from analysts for Alector Inc.?
The overall analyst consensus for ALEC is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 2 as Sell, with a median price target of $4.00.
How accurate are ALEC stock price projections?
Stock price projections, including those for Alector Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
